Indicators
Indicators
Value
Direction
MACD(12,26,9)
-1.030
Sell
RSI(14)
28.720
Sell
STOCH(KDJ)(9,3,3)
28.707
Neutral
ATR(14)
2.074
High Vlolatility
CCI(14)
-210.406
Oversold
Williams %R
89.673
Oversold
TRIX(12,20)
-0.550
Sell
StochRSI(14)
0.000
Sell
Zenas Biopharma Inc
ZBIO18.210USD
-3.950-17.82%
Close 03/27, 16:00（ET）Quotes delayed by 15 min
724.62MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Zenas Biopharma Inc
Currency: USD Updated: 2026-03-27Key Insights
Zenas Biopharma Inc's fundamentals are relatively very healthy, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 68 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 42.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Zenas Biopharma Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Zenas Biopharma Inc Highlights
StrengthsRisks
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for patients with autoimmune diseases. The Company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.
Growing
The company is in a growing phase, with the latest annual income totaling USD 10.00M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 10.00M.
Fairly Valued
The company’s latest PE is -2.16, at a medium 3-year percentile range.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 389.00 shares of this stock.
Analyst Rating
Based on
8
analysts
Strong Buy
Current Rating
42.000
Target Price
+89.53%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of Zenas Biopharma Inc is 8.67, ranking 29 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 357.08%.
Score
Financials
9.81
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.05
Operational Efficiency
10.00
Growth Potential
8.09
Shareholder Returns
7.41
Zenas Biopharma Inc's Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of Zenas Biopharma Inc is 6.00, ranking 339 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.16, which is -74.93% below the recent high of -0.54 and -548.06% above the recent low of -13.97.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 68/391
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of Zenas Biopharma Inc is 9.00, ranking 19 out of 391 in the Biotechnology & Medical Research industry. The average price target is 45.00, with a high of 55.00 and a low of 36.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
8
analysts
Strong Buy
Current Rating
42.000
Target Price
+89.53%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
548
Total
6
Median
6
Average
Company name
Ratings
Analysts
Zenas Biopharma Inc
ZBIO
8
CRISPR Therapeutics AG
CRSP
29
IQVIA Holdings Inc
IQV
27
argenx SE
ARGX
26
Beigene Ltd
ONC
24
Intellia Therapeutics Inc
NTLA
24
1
2
3
...
110
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of Zenas Biopharma Inc is 6.83, ranking 126 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 24.39 and the support level at 14.61, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
20.850
Sell
MA10
21.966
Sell
MA20
23.635
Sell
MA50
23.045
Sell
MA100
28.432
Sell
MA200
23.046
Sell
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of Zenas Biopharma Inc is 5.00, ranking 136 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 63.12%, representing a quarter-over-quarter decrease of 5.16%. The largest institutional shareholder is The Vanguard, holding a total of 1.45M shares, representing 2.53% of shares outstanding, with 8.26% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Zenas Biopharma Inc is 1.81, ranking 274 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Zenas Biopharma Inc’s latest ESG disclosure is at an average level in the Biotechnology & Medical Research industry, showing no material impact on overall risk.
Score
Beta vs S&P 500 index
--
VaR
--
240-Day Maximum Drawdown
+64.79%
240-Day Volatility
+130.96%
Return
Best Daily Return
60 days
+23.01%
120 days
+33.08%
5 years
--
Worst Daily Return
60 days
-51.86%
120 days
-51.86%
5 years
--
Sharpe Ratio
60 days
-1.28
120 days
+0.55
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+64.79%
3 years
--
5 years
--
Return-to-Drawdown Ratio
240 days
+2.00
3 years
--
5 years
--
Skewness
240 days
-0.92
3 years
--
5 years
--
Volatility
Realised Volatility
240 days
+130.96%
5 years
--
Standardised True Range
240 days
+10.95%
5 years
--
Downside Risk-Adjusted Return
120 days
+62.70%
240 days
+62.70%
Maximum Daily Upside Volatility
60 days
+136.89%
Maximum Daily Downside Volatility
60 days
+136.04%
Liquidity
Average Turnover Rate
60 days
+0.43%
120 days
+0.44%
5 years
--
Turnover Deviation
20 days
--
60 days
--
120 days
--
Peer Comparison
Biotechnology & Medical Research
Zenas Biopharma Inc
ZBIO
6.91 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Day One Biopharmaceuticals Inc
DAWN
8.26 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.21 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
